FDx Advisors Inc. increased its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 1.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 52,942 shares of the medical research company’s stock after acquiring an additional 616 shares during the quarter. FDx Advisors Inc.’s holdings in Amgen were worth $9,207,000 as of its most recent SEC filing.
A number of other institutional investors have also modified their holdings of AMGN. FMR LLC raised its stake in shares of Amgen by 4.8% in the second quarter. FMR LLC now owns 56,999,572 shares of the medical research company’s stock valued at $9,817,037,000 after buying an additional 2,587,041 shares during the period. Vanguard Group Inc. raised its stake in shares of Amgen by 0.9% in the second quarter. Vanguard Group Inc. now owns 52,146,935 shares of the medical research company’s stock valued at $8,981,266,000 after buying an additional 489,720 shares during the period. Bank of New York Mellon Corp raised its stake in shares of Amgen by 1.7% in the third quarter. Bank of New York Mellon Corp now owns 8,166,002 shares of the medical research company’s stock valued at $1,522,551,000 after buying an additional 140,117 shares during the period. Nordea Investment Management AB raised its stake in shares of Amgen by 12.9% in the second quarter. Nordea Investment Management AB now owns 7,040,599 shares of the medical research company’s stock valued at $1,212,602,000 after buying an additional 806,119 shares during the period. Finally, The Manufacturers Life Insurance Company raised its stake in shares of Amgen by 3.1% in the second quarter. The Manufacturers Life Insurance Company now owns 3,968,892 shares of the medical research company’s stock valued at $683,562,000 after buying an additional 121,202 shares during the period. Institutional investors and hedge funds own 79.53% of the company’s stock.
In related news, EVP Sean E. Harper sold 1,525 shares of the business’s stock in a transaction dated Friday, March 16th. The stock was sold at an average price of $189.75, for a total transaction of $289,368.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last 90 days, insiders have sold 4,575 shares of company stock valued at $838,064. 0.19% of the stock is owned by company insiders.
Shares of NASDAQ AMGN opened at $168.14 on Friday. The firm has a market capitalization of $125,031.95, a PE ratio of 13.37, a P/E/G ratio of 2.13 and a beta of 1.36. Amgen, Inc. has a fifty-two week low of $152.16 and a fifty-two week high of $201.23. The company has a debt-to-equity ratio of 1.35, a current ratio of 5.49 and a quick ratio of 5.17.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Thursday, February 1st. The medical research company reported $2.89 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $3.03 by ($0.14). Amgen had a net margin of 8.66% and a return on equity of 30.87%. The company had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.84 billion. During the same quarter last year, the firm posted $2.89 earnings per share. Amgen’s revenue for the quarter was down 2.7% compared to the same quarter last year. equities research analysts predict that Amgen, Inc. will post 13.25 earnings per share for the current year.
Amgen declared that its board has approved a stock buyback program on Thursday, February 1st that allows the company to buyback $10.00 billion in shares. This buyback authorization allows the medical research company to purchase shares of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s leadership believes its shares are undervalued.
The firm also recently announced a quarterly dividend, which will be paid on Friday, June 8th. Investors of record on Thursday, May 17th will be given a dividend of $1.32 per share. This represents a $5.28 annualized dividend and a yield of 3.14%. The ex-dividend date is Wednesday, May 16th. Amgen’s payout ratio is 41.97%.
Several brokerages have issued reports on AMGN. Argus upgraded Amgen from a “hold” rating to a “buy” rating and boosted their target price for the company from $192.33 to $220.00 in a research note on Tuesday, January 23rd. JPMorgan Chase boosted their target price on Amgen from $184.00 to $189.00 and gave the company a “neutral” rating in a research note on Wednesday, January 24th. Royal Bank of Canada restated a “hold” rating and issued a $189.00 target price on shares of Amgen in a research note on Wednesday, January 24th. Vetr lowered Amgen from a “hold” rating to a “sell” rating and set a $181.60 target price on the stock. in a research note on Tuesday, March 6th. Finally, BMO Capital Markets boosted their target price on Amgen from $192.00 to $202.00 and gave the company a “market perform” rating in a research note on Friday, February 2nd. Two equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have given a buy rating to the stock. Amgen currently has an average rating of “Hold” and an average price target of $190.57.
COPYRIGHT VIOLATION WARNING: This report was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another domain, it was copied illegally and reposted in violation of United States & international trademark and copyright laws. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2018/04/07/amgen-inc-amgn-position-increased-by-fdx-advisors-inc.html.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.